Norman Ng, Director of Patient Advocacy and Public Affairs at Healthcare Thinkers, shared a post on LinkedIn:
“Good morning, everyone! It’s been a long time, and I’m very happy to meet you again through “Good Medicine Hong Kong” – Time flies, we have entered January 2026, and today I would like to talk to you about the latest medical developments that have attracted much attention!
Looking back at the Pharmacy Conference in 2025, a pharmacist once proposed that there are actually many high – quality PD – 1 immunotherapy anti – cancer drugs in the mainland, but Hong Kong did not introduce them at that time. Can the public afford it?” Now, there is finally exciting news!
With the adjustment of medical funding, we hope that the authorities will fulfill their promise to use the funds saved every year to support severe patients with rare diseases, cancer, and other serious diseases, so that everyone can take medication “quickly and accurately”, and truly realize the heart – warming goal of “serious illness does not lead to poverty”. What is even more gratifying is that the “Office for the Introduction of Innovative Drugs and Medical Devices” is about to actively make efforts, from passive waiting in the past to actively advancing, which makes the industry and the public full of expectations!
The biggest breakthrough this time lies in the optimization of the drug enrollment process: not only can cancer drugs be directly included in the category of special drugs, but new domestic drugs can also skip additional procedures and directly enter the HA’s drug formulary and safety net! This means that cancer patients can use cancer drugs independently developed by our country and come to different countries faster and affordably, without having to wait for a long time through the cumbersome approval process in the past, which is really an important progress that benefits patients.
Of course, although good medicine has a price, we also hope that the medical security mechanism can continue to be optimized. Asset review and regular sampling of existing safety nets consume a lot of manpower, material resources and time, and may not be the most cost – effective method. Hong Kong has a large middle class, and many patients (especially cancer patients) are willing to share medical costs through the “co – pay” mechanism, rather than relying solely on the safety net or paying for it entirely out of pocket. We look forward to breaking out of the existing framework and designing a reasonable common prosperity mechanism to avoid repeating the problem of excessive profits in medical insurance in some Western countries, so that medical resources can be truly used on the cutting edge.
Finally, let us look forward to the initiative of the “Office for the Introduction of Innovative Drugs and Medical Devices” to bring more medical benefits! Thank you all for watching, we will meet next time, bye – bye.
Watch the video.”
More posts featuring Norman Ng